CNS Pharmaceuticals Files 8-K

TL;DR

CNS Pharmaceuticals filed an 8-K with updated HQ info in Houston, TX.

AI Summary

On October 23, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027. The company is incorporated in Nevada and its IRS number is 822318545.

Why It Matters

This filing provides updated corporate information and addresses for CNS Pharmaceuticals, Inc., which is important for investors and stakeholders to have the most current contact and location details.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain material financial or operational news.

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Registrant
• 2100 West Loop South, Suite 900, Houston, Texas 77027 (location) — Principal executive offices
• Nevada (jurisdiction) — State of incorporation
• 822318545 (identifier) — IRS Employer Identification No.
• October 23, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
• $1.00 — d not maintained a closing bid price of $1.00 per share (the "Minimum Bid Price Requi

Filing Documents

• cns_8k.htm (8-K) — 29KB
• 0001683168-24-007304.txt ( ) — 202KB
• cnsp-20241023.xsd (EX-101.SCH) — 3KB
• cnsp-20241023_lab.xml (EX-101.LAB) — 33KB
• cnsp-20241023_pre.xml (EX-101.PRE) — 24KB
• cns_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously disclosed, on September 12, 2024, CNS Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") notifying the Company that for the previous 30 consecutive business days the Company's common stock had not maintained a closing bid price of $1.00 per share (the "Minimum Bid Price Requirement") required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) because the Company effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company requested a hearing before a Hearings Panel (the "Panel"), which hearing will take place on November 5, 2024. The hearing automatically stayed any suspension or delisting action pending the hearing and the expiration of any additional extension period if granted by the Panel following the hearing. There can be no assurance that the Panel will grant the Company an additional extension period beyond the date of hearing. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: October 23, 2024 3